From blood sample to variant data, comprehensive NGS solutions for analysis from a single tube of blood

Whether you are looking at multiple targets or just a few, our next-generation sequencing (NGS) solutions combine the power of Ion Torrent technology with manual or automated extraction of cell-free nucleic acid; relevant, targeted NGS assays; digital PCR for orthogonal verification; and advanced isolation of circulating tumor cells (CTCs). Together, these solutions enable a more complete understanding of a tumor’s molecular profile using research blood samples.

Enabling access to tumor biology

 “What’s in the blood is actually what’s relevant. One could argue it’s not the overall tumor composition that we really want. We want the biologically relevant population. How do we define that? If that’s in the blood, that’s what we should be sampling—it’s that global representation of tumor biology that we need.”

—Minetta Liu, MD
Associate Professor of Oncology, Mayo Clinic

Learn more about cell-free DNA (cfDNA) in cancer research

It’s time to start thinking about using blood samples in your cancer research. This installment of our #SeqItOut series addresses input amount, DNA yield, and expected performance from a targeted NGS assay.

Professor José Luis Costa, PhD, IPATIMUP, discusses use of cfDNA to detect rare mutations in lung cancer research blood samples. 

Luca Quagliata, MD, University Hospital, Basel, Switzerland, talks about his research tracking mutations in metastatic prostate cancer samples using cfDNA and CTCs.

The road from research blood sample to variant data

The NGS process starts with cell-free nucleic acid extraction and sample preparation from a single tube of blood. The amplified sample will undergo high-throughput semiconductor sequencing, with results analyzed and reported through an integrated bioinformatics solution.

Ion Torrent Oncomine 2-day liquid biopsy NGS workflow.

The power of next-generation sequencing

Next-generation sequencing (NGS) can process hundreds to thousands of genes and detect multiple biomarkers simultaneously. The sequencing chip is partitioned into millions of wells (flow cells) that allow reactions to occur independently in each well, enabling high-throughput sequencing of many genes alongside detection of biomarker variations at the same time. In contrast, traditional technologies such as FISH, IHC and PCR can only analyze one target gene at a time.

Liquid biopsy solutions for NGS

Enrich your cfDNA and cfRNA sample with a phenol-free method in less than 40 minutes

Amplify cfDNA and cfRNA with our proprietary amplification-based technology to generate amplicon libraries

Prepare your library template and load chips with an automated, overnight run

Sequence from 2 M to 80 M reads per run with just one instrument, matching your throughput and application needs to our portfolio of sequencing chips

Other liquid biopsy applications

Detect and quantify rare mutations at frequencies down to 0.1%, and utilize for orthogonal verification of NGS results

Understand tumor heterogeneity with concurrent analysis of CTCs and cfDNA from a single sample

Isolate, characterize, and analyze RNA and protein content from living cancer cells

Webinars on Oncomine cfDNA studies and results

A multi-center lung cancer cell-free DNA study

  • Dr. Nicola Normanno presents the results of an international multi-center study
  • Focus on tumor heterogeneity and evolution that could change treatment decisions in the future

Mutation analysis of cfDNA in a lung tumor

  • Dr. José Luis Costa presents data obtained running cfDNA from plasma samples on the Ion S5 System
  • Focus on expected results from a research study monitoring a lung tumor

Variant detection in cell-free DNA from NSCLC using NGS

  • Dr. Tracy Stockley presents the utilization of NGS and cell-free DNA for detection of EGFR T790M resistance mutation
  • Focus on mutation detection in cell-free DNA and comparison with droplet digital PCR technology

EGFR mutation monitoring in blood samples

  • Dr. Bea Bellosillo presents findings from monitoring non-small cell lung cancer (NSCLC) samples using digital PCR
  • Focus on mutation detection in circulating cell-free tumor DNA and tracking of tumor dynamics